antiviral drugs

Finally, there are antiviral drugs that will keep people with COVID out of the hospital (and the morgue). But, good luck getting a prescription if you should need it. The FDA has pretty much guaranteed that this will be almost impossible. Here's why.
Emergency Use Authorization (EUA) from the FDA is the exception, not the rule. Except for COVID therapies. Three vaccines and one drug have EUA in the US. Merck is now seeking EUA for its antiviral drug molnupiravir. Should it be granted?
The New York Times (correctly) reports that a COVID pill is needed, not just a vaccine. But the paper also tells this story in its typically biased manner, implying that the government, not drug companies, discover drugs. It's a bunch of nonsense that dates back to... forever.
A Medscape article entitled "Five-Day Course of Oral Antiviral Appears to Stop SARS-CoV-2 in Its Tracks" was recently published. Don't fall for the title. It's not that simple.
More than six months after the hype of repurposed COVID drugs, we have nothing. But this wasn't at all unexpected. Here's why.
We got some very good news in the past week. Vaccines from Pfizer and Moderna greatly exceeded expectations. But Drs. Seley-Radtke and Bloom argue in the Duluth News Tribune that antiviral drugs will still be needed, no matter how good the vaccines are.
Another clinical trial of remdesivir – this time with hospitalized patients having moderate COVID-19 – yielded disappointing and strange results. The first randomized trial showed a modest benefit in patients with severe COVID, so theoretically the drug should have worked better in patients who weren't as sick. But, it didn't.
Vaccines for COVID-19 get most of the headlines. But it is possible, if not likely, that a drug or combination of drugs may be quicker to develop, and possibly will be more effective in controlling the virus. Here's an opinion piece making the case that recently ran in the Baltimore Sun, co-authored by ACSH's Dr. Josh Bloom and ACSH advisor Dr. Katherine Seley-Radtke.
Remdesivir arrived with great hope and even greater expectations. Would this drug finally awake us from the 2-plus-month long nightmare that has the U.S. tossing and turning in its sleep? As things stand now that answer is no. Here's why.
After months of speculation, the results of the first placebo-controlled trial of remdesivir are out. The drug does help people with COVID-19 disease, but it's nothing to get excited about. Here's why.
In the frantic fight to get an effective antiviral into the hands of a terrified world, there's a new kid on the block. This one is called N-hydroxycytidine and it's rather interesting. NHC is a potent inhibitor of coronavirus replication in cells, it's really easy to synthesize and it'll protect you from the virus. (That is, if you're a lab rodent.)
For a simple drug, there sure is a lot of controversy surrounding hydroxychloroquine -- a malaria drug that's one of a handful of repurposed drugs being evaluated as potential anti-coronavirus treatments. However, hydroxychloroquine (HCQ) doesn't look especially promising. Dr. Katherine Seley-Radtke, Professor of Chemistry and Biochemistry at the University of Maryland-Baltimore County, explains.